(Last updated : 2020-07-04 11:05:09)
  Mikio Oka
   Department     ,
   Position  
■ Present specialized field
Respiratory medicine, Immunology 
■ BooK
1. 2019/03   Immune Surveillance and Biomarkers for Immune-checkpoint Therapy in Lung Cancer, 2018 RIKEN Annual Report 
■ Journal
1. 2019/12/01 Serum Antibody against NY-ESO-1 and XAGE1 Antigens Potentially Predicts Clinical Responses to Anti-Programmed Cell Death-1 Therapy in NSCLC. 
2. 2018/09 A recurrent case of eosinophilic pneumonia with high IL-25 levels. 
3. 2018/10 Deciduoid type malignant pleural mesothelioma: a case report 
4. 2017/05 NY-ESO-1 protein cancer vaccine with poly-ICLC and OK-432: rapid and strong induction of NY-ESO-1-specific immune responses by poly-ICLC 
5. 2016/12 Survival of Lung Adenocarcinoma Patients Predicted from Expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on Tumor Cells and Tumor-Infiltrating T Cells. 
Display all(150)
■ Presentation
1. 2019/11/17 Immunological monitoring markers of clinical responses to anti-PD-1 therapy for non-small-cell lung cancer  
2. 2019/09/25 Serial antibody responses to XAGE1 and NY-ESO-1 antigens during anti-PD-1 therapy for non-small-cell lung cancer  
3. 2019/02/28 Serum NY-ESO-1 and XAGE1 Antibodies as Predictive Biomarkers in Anti-PD-1 Therapy for Non-Small-Cell Lung Cancer  
4. 2018/10/02 Serum antibody against NY-ESO-1 and XAGE1 predicts clinical responses to anti-PD-1 therapy in non-small-cell lung cancer.  
5. 2018/01/26 Clinical significance of humoral immunity against XAGE1 cancer-testis antigen in lung adenocarcinoma  
Display all(125)